• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性淋巴细胞白血病的临床分期及预后标志物

Clinical staging and prognostic markers in chronic lymphocytic leukemia.

作者信息

Rai Kanti R, Wasil Tarun, Iqbal Uzma, Driscoll Nancy, Patel Dilip, Janson Dale, Mehrotra Bhoomi

机构信息

Long Island Jewish Medical Center, Division of Hematology-Oncology, 270-05 76th Avenue, New Hyde Park, NY 11040, USA.

出版信息

Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii. doi: 10.1016/j.hoc.2004.04.001.

DOI:10.1016/j.hoc.2004.04.001
PMID:15325699
Abstract

In this article we provide a brief review of the two staging systems in chronic lymphocytic leukemia, and we discuss the more recently identified, new prognostic markers that are of interest to clinicians and researchers in this field.

摘要

在本文中,我们简要回顾了慢性淋巴细胞白血病的两种分期系统,并讨论了该领域临床医生和研究人员感兴趣的、最近新发现的预后标志物。

相似文献

1
Clinical staging and prognostic markers in chronic lymphocytic leukemia.慢性淋巴细胞白血病的临床分期及预后标志物
Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii. doi: 10.1016/j.hoc.2004.04.001.
2
Prognostic factors and clinical staging in chronic lymphocytic leukemia.慢性淋巴细胞白血病的预后因素与临床分期
Hematol Oncol Clin North Am. 1990 Apr;4(2):447-56.
3
Prognostic markers in chronic lymphocytic leukaemia.慢性淋巴细胞白血病的预后标志物
Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68. doi: 10.1016/j.beha.2007.02.001.
4
Smudge cells, serum albumin, and prognosis in B-cell chronic lymphocytic leukemia.涂抹细胞、血清白蛋白与B细胞慢性淋巴细胞白血病的预后
J Clin Oncol. 2009 Aug 1;27(22):e44; author reply e45. doi: 10.1200/JCO.2009.23.8188. Epub 2009 Jul 6.
5
Risk stratification in chronic lymphocytic leukemia.慢性淋巴细胞白血病的风险分层
Semin Oncol. 2006 Apr;33(2):186-94. doi: 10.1053/j.seminoncol.2006.01.017.
6
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.CD49d表达是早期慢性淋巴细胞白血病疾病进展的独立危险因素。
Haematologica. 2008 Oct;93(10):1575-9. doi: 10.3324/haematol.13103. Epub 2008 Jul 18.
7
Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者诊断及治疗时预后因素在风险分层中的应用。
Curr Opin Hematol. 2006 Jul;13(4):266-72. doi: 10.1097/01.moh.0000231425.46148.b0.
8
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.慢性淋巴细胞白血病:新的预后因素及其与风险适应性治疗策略的相关性。
Haematologica. 2005 Mar;90(3):391-9.
9
[Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].[慢性淋巴细胞增殖性疾病白血病类型的临床和实验室预后参数]
Acta Med Croatica. 2008 Oct;62(4):351-64.
10
Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients). French Cooperative Group on Chronic Lymphocytic Leukemia.
Nouv Rev Fr Hematol (1978). 1988;30(5-6):363-7.

引用本文的文献

1
Evaluation of the Findings of Peripheral Blood Smear, Bone Marrow Aspiration and Biopsy, Iron Storage, and Immunophenotype in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者外周血涂片、骨髓穿刺与活检、铁储存及免疫表型检查结果的评估
Iran J Pathol. 2024 Spring;19(2):152-159. doi: 10.30699/IJP.2024.2011275.3170. Epub 2024 Jan 29.
2
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.基于治疗和分子因素的加拿大大型集中性 CLL 临床十年预后分析。
Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472.
3
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤退伍军人接受下一次治疗的时间、医疗保健资源利用情况及与使用依鲁替尼相关的费用:一项真实世界回顾性分析
J Manag Care Spec Pharm. 2020 Oct;26(10):1266-1275. doi: 10.18553/jmcp.2020.20095. Epub 2020 Sep 3.
4
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.根据无治疗间隔时间长度更新慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(CLL/SLL)患者的生存估计。
Leuk Lymphoma. 2018 Mar;59(3):643-649. doi: 10.1080/10428194.2017.1349905. Epub 2017 Jul 18.
5
Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.通过ZAP70的高分辨率免疫表型分析对慢性淋巴细胞白血病的预后信息和生物学见解
Cytometry A. 2014 Sep;85(9):798-808. doi: 10.1002/cyto.a.22485. Epub 2014 May 20.
6
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.美国食品和药物管理局批准:利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者。
Oncologist. 2011;16(1):97-104. doi: 10.1634/theoncologist.2010-0306. Epub 2011 Jan 6.
7
Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.与人类13q14存在同线性的异常微小RNA - 16基因座与新西兰黑小鼠的慢性淋巴细胞白血病相关。
Blood. 2007 Jun 15;109(12):5079-86. doi: 10.1182/blood-2007-02-071225. Epub 2007 Mar 9.
8
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.B细胞慢性淋巴细胞白血病/小淋巴细胞淋巴瘤:ZAP70检测在骨髓活检标本中的作用
J Clin Pathol. 2007 Jun;60(6):627-32. doi: 10.1136/jcp.2006.039586. Epub 2006 Aug 17.